Michael Gwinner, PhD, Vice President and Senior General Manager, Radioligand Therapy, Oncology at Novartis
For decades, precision medicine has been oncology's North Star – the promise of treatments tailored to specific patient and tumor characteristics rather than one-size-fits-all approaches. Today, radioligand therapies (RLTs) are delivering on that promise and oncologists across the country have taken note, as demonstrated by increased demand.
As institutions integrate RLTs into their comprehensive cancer centers, demand for these precision therapies continues to grow. RLTs represent the convergence of precision medicine and targeted drug delivery – combining a tumor-targeting compound with a therapeutic radioisotope to deliver radiation directly to cancer cells while sparing healthy tissue.
With the global RLT market projected to exceed $40 billion in the next decade and hundreds of pipeline projects in development industry-wide, we are entering an exciting era for RLT. But the success of RLT depends not only on the clinical, efficacy, and safety profiles of these therapies but equally as much on manufacturing and delivery excellence.
Building a Delivery Network for the Future of RLT
At Novartis, we've created a specialized manufacturing and supply chain network designed to meet growing demand while maintaining precision. By vertically integrating every aspect of the RLT process – from isotope production to final delivery – we've established a system that enables reliable access to these therapies nationwide.
Our facilities in Millburn, New Jersey, and Indianapolis, Indiana, form the backbone of this manufacturing network, with a third US site in Carlsbad, California, scheduled to launch in the future. With a deep commitment to US manufacturing, we are making additional investments to bolster our end-to-end supply chain by building 2 new RLT facilities in Florida and Texas, as well as expanding existing facilities over the next 5 years. These facilities are strategically located to ensure coast-to-coast coverage – with the Indiana site serving nearly one-half of the US population within a 12-hour driving radius.
These specialized manufacturing and courier networks as well as supporting teams and processes are the foundation of our delivery success, enabling us to achieve greater than 99% on-time delivery of RLT treatments. Our facilities feature purpose-built innovation with fully automated production lines – a first in the radiopharmaceutical industry – and on-site radioisotope production capabilities. These sites are designed with room for expansion to accommodate future growth and enable manufacturing of different isotopes, ligands, and RLTs as the field advances.
Supporting Treatment Center Excellence and Expansion
Our vision extends beyond manufacturing to creating a complete ecosystem that supports institutions in delivering cutting-edge care.
As innovative therapies enter clinical practice, health care providers need tools and resources to support efficient implementation. Beyond reliable manufacturing, successful adoption of RLT requires addressing implementation barriers that could otherwise limit patient access.
To address these needs, we developed The Novartis RLT Institute in collaboration with health care providers to provide resources that address implementation challenges. The comprehensive suite of resources includes standardized protocols, training materials, and operational guidance for health care professionals looking to establish or expand RLT capabilities at their institutions and help health care teams focus on patient care.
With over 600 treatment sites across the United States and more than 150 additional sites planned this year, this growing network ensures RLT is available to patients in their local communities and demonstrates the health care system's confidence in this therapeutic approach.
Delivering on RLT’s Promise
Collaboration is essential to advancing the next era of RLT. As cancer centers establish RLT programs, we're working alongside partners to strengthen the power of RLTs and broaden the number of people who can benefit from them by, for example, developing novel isotopes and ligands and researching combination therapies for additional cancer types including breast, colon, lung, and pancreatic cancer, while also bringing this modality to earlier stages of disease and lines of treatment.
This approach accelerates innovation with hundreds of pipeline projects currently in development across the industry. We're ensuring our manufacturing capabilities can scale with each new advancement, aligning with our 30-year commitment to reimagine medicine.
The future of complex, time-sensitive therapies like RLT depends on our collective ability to innovate beyond the molecule. As the pharmaceutical industry continues to develop breakthrough treatments with unique manufacturing requirements, we must rethink care delivery, from bench to bedside. The experience gained from building reliable RLT networks, inclusive of the many partners who touch the treatment, offers valuable lessons for addressing similar challenges across therapeutic areas.
To learn more, visit RLTInstitute.com.
4/25 FA-11393351